Paolo A. Ascierto Director of the Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics at the National Tumor Institute, Naples, Italy. He obtained his medical degree from the University of Naples, the same institution where he subsequently earned his Board Certification in Oncology. He went on to serve consecutive positions at the National Tumor Institute in Naples, as a postdoctoral fellow and then as Vice Director of the Department of Clinical Immunology.
Professor Ascierto’s research interests include the genetics and proteomics of melanoma, assessment of new molecular markers for tumor progression, biochemical and immunological monitoring, immunotherapy and vaccination treatments in solid tumors, and combination strategies with I-O. He has been the Principal Investigator in over 80 clinical trials and is an active member in several international medical societies. He is a member of the Steering Committee of Society of Melanoma Research (SMR) since 2016, the board of Cancer Development Drug Forum (CDDF) since 2017, the Board of Directors of Society of Immuno Therapy of Cancer (SITC) since 2018, and President of the Fondazione Melanoma Onlus since 2010, and of Campania Society of ImmunoTherapy of Cancer (SCITO) since 2013. He is an active reviewer for several international journals including, NEJM, JCO, Lancet Oncology, and Clinical Cancer Research, as well as an Associate Editor for Onco-Immunology of Annals of Oncology, Chief Section Editor for Combination Strategies section of Journal of Translational Medicine, Chief Section Editor of Expert Reviews of Immunology Vaccines and Informatics, and Associate Editor of Journal of ImmunoTherapy of Cancer. He is the author of more than 300 publications in peer-reviewed journals. Such journals include: The New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, and Clinical Cancer Research, among others.